Adverum Biotechnologies Announces Positive Results in Preclinical Study of ADVM-022 Gene Therapy in Wet AMD

May 1, 2018

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced long-term preclinical efficacy data on ADVM-022 in a non-human primate model of wet age-related macular degeneration (wAMD). In this preclinical study, the efficacy of ADVM-022 at 13 months post-administration was consistent with earlier reported data, demonstrating that a single intravitreal injection of ADVM-022 was found to be safe and statistically significant (p<0.0001) in preventing the development of Grade IV lesions compared to the vehicle control group. ADVM-022 induced long-term efficacy that was comparable to aflibercept, an anti-Vascular Endothelial Growth Factor (VEGF) standard-of-care therapy. ADVM-022 was well tolerated, with no serious adverse events.

“We continue to be encouraged by the efficacy and sustained protein levels we are seeing a year post a single intravitreal injection of ADVM-022,” said Mehdi Gasmi, Ph.D, chief science and technology officer of Adverum Biotechnologies. “These durable efficacy data support our plans to advance ADVM-022 into the clinic and we remain on track to submit an Investigational New Drug (IND) Application for ADVM-022 in the second half of this year. We are excited to be working on a gene therapy candidate that has demonstrated the potential to alleviate the treatment burden of frequent injections for patients living with wet AMD.”

ADVM-022 utilizes a proprietary vector capsid (AAV.7m8) carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is administered as a single intravitreal injection. VEGF overexpression can lead to wAMD progression and vision loss.  Treatment with ADVM-022 is designed to minimize the burden of frequent anti-VEGF injections, the current standard-of-care treatment for wAMD.


CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.